Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
Clinical trial NCT03299049 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03299049
- Sponsor
- ViiV Healthcare
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-27
- Primary completion
- 2019-06-06
- Enrollment
- 1049
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.